Lijie Han

966 total citations
42 papers, 465 citations indexed

About

Lijie Han is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lijie Han has authored 42 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Hematology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lijie Han's work include Hematopoietic Stem Cell Transplantation (10 papers), Gut microbiota and health (6 papers) and Acute Lymphoblastic Leukemia research (6 papers). Lijie Han is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Gut microbiota and health (6 papers) and Acute Lymphoblastic Leukemia research (6 papers). Lijie Han collaborates with scholars based in China, Lebanon and United Kingdom. Lijie Han's co-authors include Qifa Liu, Jie Peng, Li Xuan, Fen Huang, Lizhi Zhou, Zhiping Fan, Hua Jin, Zhongxing Jiang, Dan Zou and Min Dai and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Lijie Han

37 papers receiving 462 citations

Peers

Lijie Han

ONCOL

HEMAT

IMMUN

PRM

Edgar Faber Czechia

Runzhe Chen China

Shigeru Takamoto Japan

Rafael Ríos Spain

Jameel Muzaffar United States

Iris M. De Cuyper Netherlands

David Wages United States

Étienne Paubelle France

Donata Urbaniak‐Kujda Poland

Anne‐Marie Quirke United Kingdom

Edgar Faber Czechia

Lijie Han

168 ×1.0

ONCOL

150 ×0.9

401 ×2.6

HEMAT

111 ×1.3

IMMUN

43 ×0.5

PRM

Citations per year, relative to Lijie Han Lijie Han (= 1×) peers Edgar Faber

Countries citing papers authored by Lijie Han

Since Specialization

Citations

This map shows the geographic impact of Lijie Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lijie Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lijie Han more than expected).

Fields of papers citing papers by Lijie Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lijie Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lijie Han. The network helps show where Lijie Han may publish in the future.

Co-authorship network of co-authors of Lijie Han

This figure shows the co-authorship network connecting the top 25 collaborators of Lijie Han. A scholar is included among the top collaborators of Lijie Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lijie Han. Lijie Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Lijie, Ke Wang, Zhongxing Jiang, Xuejun Guo, & Jifeng Yu. (2025). Recent development in bispecific antibody immunotherapy for hematological malignancies. Critical Reviews in Oncology/Hematology. 212. 104752–104752. 2 indexed citations

Wang, Ye, et al.. (2025). A cross sectional study of the diabetes mediated GGT to HDL ratio and cognitive function in older adults. Scientific Reports. 15(1). 20928–20928.

Yang, Wei, Sujun Gao, Xiaojing Yan, et al.. (2024). Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).. Journal of Clinical Oncology. 42(16_suppl). 6510–6510.

Peng, Jie, et al.. (2024). A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma. Journal of Translational Medicine. 22(1). 87–87. 14 indexed citations

Jin, Shu, et al.. (2024). Thyroid Gland as a Metastatic Site for Hepatocellular Carcinoma: A Rare Case Report. OncoTargets and Therapy. Volume 17. 1033–1039.

Jiang, Yongsheng, Lijie Han, Jian Yang, et al.. (2023). Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma. Cancer Immunology Immunotherapy. 72(8). 2701–2716. 5 indexed citations

Peng, Jie, et al.. (2023). Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study. Cancer Cell International. 23(1). 262–262. 1 indexed citations

Han, Lijie, Haiyan Zhang, Ping Ma, et al.. (2022). Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation. Annals of Hematology. 101(6). 1283–1294. 6 indexed citations

Han, Lijie, Yilu Li, Jiaying Wu, et al.. (2022). Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1. International Journal of Hematology. 116(6). 892–901. 5 indexed citations

10.

Peng, Jie, Jing Zhang, Dan Zou, et al.. (2022). Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Frontiers in Immunology. 13. 960459–960459. 13 indexed citations

11.

Peng, Jie, Lushan Xiao, Dan Zou, & Lijie Han. (2022). A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer. Frontiers in Medicine. 9. 808378–808378. 6 indexed citations

12.

Xu, Na, Ke Zhao, Lijie Han, et al.. (2021). Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia. Cancer Letters. 510. 59–66. 3 indexed citations

13.

Bi, Nan, Hong Ge, Lin Zhang, et al.. (2021). OA02.06 PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC. Journal of Thoracic Oncology. 16(3). S105–S106. 1 indexed citations

14.

Peng, Jie, et al.. (2020). Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma. OncoImmunology. 9(1). 1734156–1734156. 19 indexed citations

15.

Han, Lijie, Ke Zhao, Yuanyuan Li, et al.. (2019). A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation. American Journal of Transplantation. 20(4). 1014–1027. 32 indexed citations

16.

Han, Lijie, Feifei Wu, Jie Ma, et al.. (2019). Therapeutic efficacy and safety of domestic bortezomib-based chemotherapy in treatment of multiple myeloma. 28(5). 267–271.

17.

Han, Lijie, Hua Jin, Lizhi Zhou, et al.. (2018). Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients. Frontiers in Immunology. 9. 669–669. 69 indexed citations

18.

Zhang, Yanli, et al.. (2017). Interferon and arsenic trioxide combined with tyrosine kinase inhibitors for treatment of chronic myeloid leukemia with primary T315I mutation: report of one case and review of literature. 26(5). 297–299. 1 indexed citations

19.

Zhou, Jian, Yanli Zhang, Yuewen Fu, et al.. (2016). [Outcome analysis of allogeneic hematopoietic stem cell transplantation for 41 patients with severe aplastic anemia].. PubMed. 37(8). 661–5. 1 indexed citations

20.

Liu, Sha, Xudong Wei, Qingsong Yin, et al.. (2015). [Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia:nine cases report and literatures review].. PubMed. 36(3). 241–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact